
    
      An open-label randomized (1:1) phase 2 study between a standard arm of VRD light versus an
      experimental arm of selinexor in combination with lenalidomide/ bortezomib and dexamethasone
      to newly diagnosed transplant in-eligible symptomatic multiple myeloma patients in a
      multicenter international set-up with in the Nordic Multiple Myeloma Study Group.

      Each arm will include 50 patients with a total number of participants of 100 patients,
      recruited within the NMSG collaborating countries. After induction patient will be treated
      with continued lenalidomide-dexamethasone according to SWOG, with continuous 40mg selinexor
      weekly in the selinexor arm (experimental arm B).
    
  